-
1. Bishop J. R., Schuksz M., Esko J.D.: Heparan sulphate proteoglycans fine-tune mammalian in physiology. Nature, 446, 1030, 2007.
-
2. Dallinga G.M. et al.: The metabolism of triglyceride-rich lipoproteins revisited: New players, new insight. Atherosclerosis, 211, 1-8, 2010.
-
3. De Muro P. et al.: Urinary glycosaminoglycans composition in chronic glomerulonephritis. J Nephrol., 18, 154-160, 2005.
-
4. Fogelstrand P., Boren J.: Retention of atherogenic lipoproteins in the artery wall and its role in atherogenesis. Nutrition, metabolism & Cardiovascular Diseases, 22, 1-7, 2012.
-
5. Hosono-Fukao T. et al.: Heparan Sulfate subdomains that are degraded by sulf accumulate in cerebral amyloid β plaques of Alzheimer’s disease. Am J Pathol., 180, 2056-2067, 2012.
-
6. Jefferson A., Shankland S.J., Pichler R.H.: Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney International, 74, 22-36, 2008.
-
7. Ki rn-Saf ran C., Farach-Carson M.C., Carson D. D.: Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans. Cell. Mol. Life Sci., 66, 3421-3434, 2009.
-
8. Kolset S.O., Salmivirta M.: Cell surface heparan sulfate proteoglycans and lipoprotein metabolism. Cellular and molecular life sciences, 56, 857, 1999.
-
9. Lahdesmaki K. et al.: Acidity and lipolysis by group V secreted phospholipase A(2) strongly increase the binding of apoB-100- containing lipoproteins to human aortic proteoglycans. Biochim Biophys Acta, 1821, 257, 2012.
-
RELATION NAME